- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Michael Cohen Contrasts the Manifestation and Treatment of Wet vs Dry AMD
Michael N. Cohen, MD, a retinal surgeon at Wills Eye Hospital and Mid Atlantic Retina, describes the differences between wet and dry age-related macular degeneration (AMD) and how gene therapy could help treat the condition in the future.
Transcript
How does geographic atrophy differ from other forms of age-related macular degeneration and how can gene therapy address it?
Cohen: So, macular degeneration comes in 2 types: dry and wet. We have excellent treatment for the wet form of the disease, which is when blood vessels grow underneath the retina.
The dry form of the disease is a little different. Early on, this is marked by several findings we see in the retina, that buildup called drusen. As things progress over time, it can lead to atrophy or loss of cells at the outer retina, which can be pretty visually devastating.
Right now, we have no treatment in terms of really effectively dealing with it. The route of administration of a lot of our medications is injections into the vitreous cavity. And so, there are always potential risks involved with this, even though they're quite small. But it is a burden some issue to patients in terms of needing quite a high number of injections to control their disease right now and that's what we see in the wet form of macular degeneration. The hope of gene therapy is that even though the route of administration is the same injection into the vitreous cavity, it has the potential for a much, much longer lasting effect, which would really limit that injection burden.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
AUA Session Highlights the General Urologist’s Role in Gender-Affirming Care
May 7th 2024During her session, Polina Reyblat, MD, Kaiser Permanente Los Angeles Medical Center, highlighted best practices urologists should incorporate to make transgender and gender-diverse patients comfortable during physical exams and avoid retraumatization.
Read More
